Physician profile
James M Wilson
NPI 1194827337
$3,262.68
in general payments reported to CMS, 2019-2025
19 companies · $578 in 2025
The $578 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $110 · 2021: $743 · 2022: $823 · 2023: $39.21 · 2024: $19.62 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579 · Education: $58.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.58 |
| Education | $58.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,350.17 | 2019-2022 | |
| Abiomed | $484.31 | 2019 | |
| Cathworks, INC. | $230.75 | 2022 | |
| Alphatec Spine, INC | $141.04 | 2019 | |
| Janssen Pharmaceuticals, INC | $130.67 | 2019-2020 | |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Amgen INC. | $110.64 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $95.31 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.21 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $94.19 | 2025 | Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.27 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $70.17 | 2023-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $46.94 | 2025 | Wegovy |
| Medtronic, INC. | $45.29 | 2022-2023 | Mycarelink |
| Azurity Pharmaceuticals, INC. | $42.74 | 2025 | Edarbi, Alvesco |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $38.97 | 2021-2022 | |
| Bridgebio Pharma, INC. | $35.86 | 2025 | Attruby |
| Boston Scientific Corporation | $23.89 | 2019 | |
| Pfizer INC. | $20.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.